Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Tianjin (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
52 fő, tervezett
Kezdés
2021. szept. 1.
Tervezett befejezés
2025. szept. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Avatrombopag
A regiszteradat frissítve
2025. február 24.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with immune thrombocytopenia (ITP, low platelets caused by the immune system) with autoantibodies. Eltrombopag or herombopag must not have worked, or could not be taken.

Életkor
18 years and older
Nem
Men and women
A betegség stádiuma
ITP linked to connective tissue disease (such as lupus, Sjogren's syndrome or rheumatoid arthritis), ITP with a positive antinuclear antibody test, Evans syndrome, or ITP with a positive Coomb's test. Platelet count below 30 ×10^9/L at screening.
Korábbi kezelés
Eltrombopag (75 mg/d) or Herombopag (7.5 mg/D) for at least 4 weeks did not work or stopped working, or could not be used, tolerated or was refused. Other ITP treatment must be finished, or stable or being lowered within 2 weeks before joining. No rituximab within 3 months.
Biomarker vagy leletérték
Autoantibodies: positive antinuclear antibody or positive Coomb's test, or a connective tissue disease.

A részvétel fő kizáró okai

  • Avatrombopag did not work before (40mg once a day for more than 4 weeks)
  • Blood clot within 3 months with risk factors, or use of blood thinners or antiplatelet drugs
  • Spleen removal within 3 months or planned within 3 months
  • Lupus affecting the brain or kidneys, cataract, or active infection
  • Pregnant or breastfeeding women, or planning pregnancy during the trial

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • The patients have provided written informed consent prior to enrollment
  • Men and women greater than or equal to 18 years of age
  • Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome
  • Platelet count<30 ×10\^9/L at screening
  • Patients who have previously failed to receive Eltrombopag or Herombopag [poor efficacy (Eltrombopag 75 mg/d or Herombopag 7.5 mg/D, at least 4 weeks), or the efficacy cannot be maintained], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment
  • Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment
  • Effective contraceptive measures will be taken during the clinical trial

Ki nem vehet részt

  • Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening
  • Those who had received rituximab within 3 months
  • Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks)
  • Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months
  • There are surgical planners during the study
  • Patients that had participated in other experimental researches within one month before enrollment
  • Patients with active thyroid disease requiring treatment
  • Subjects known to be allergic to Avatrombopag or any of its excipients
  • Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening
  • Existing hepatitis B virus, hepatitis C virus replication or HIV infection
  • Patients with severe cardiac or pulmonary dysfunction
  • History of psychiatric disorder
  • Patients with a history of drug/alcohol abuse (within 2 years before the study)
  • Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase > 3×ULN)
  • Severe renal damage (creatinine clearance < 30 ml/min)
  • Patients with lupus encephalopathy or lupus nephritis
  • Patients with cataract
  • Pregnant or lactating women or those planning to be pregnant during the trial
  • Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial

Helyszínek itt: Kína

  • Institute of Hematology & Blood Diseases HospitalTianjin, KínaContact: Rongfeng Fu, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

A vizsgálat csoportja

  • Treatment groupA vizsgált kezelés

    Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag

    Kezelés: Avatrombopag

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. február 24.